3 Stocks Dragging In The Drugs Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.37. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 1.75.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.39 (-0.7%) to $51.96 on average volume Thus far, 955,421 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $51.49-$52.04 after having opened the day at $51.91 as compared to the previous trading day's close of $52.35.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $64.6 billion and is part of the health care sector. The company has a P/E ratio of 10.4, below the S&P 500 P/E ratio of 17.7. Shares are up 9.4% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AstraZeneca Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Novartis ( NVS) is down $0.70 (-0.9%) to $73.92 on heavy volume Thus far, 1.2 million shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $73.24-$74.51 after having opened the day at $74.37 as compared to the previous trading day's close of $74.62.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $183.4 billion and is part of the health care sector. The company has a P/E ratio of 19.2, above the S&P 500 P/E ratio of 17.7. Shares are up 17.9% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Pfizer ( PFE) is down $0.19 (-0.7%) to $29.11 on average volume Thus far, 24.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 32.7 million shares. The stock has ranged in price between $28.85-$29.33 after having opened the day at $29.08 as compared to the previous trading day's close of $29.30.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $204.1 billion and is part of the health care sector. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Shares are up 16.8% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC